VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the stock.

Several other research firms have also commented on VNRX. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of VolitionRx in a research report on Tuesday, March 4th.

VolitionRx Price Performance

VNRX opened at $0.59 on Wednesday. The company’s 50 day simple moving average is $0.61 and its two-hundred day simple moving average is $0.65. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.09. The firm has a market capitalization of $54.58 million, a price-to-earnings ratio of -1.64 and a beta of 1.09.

Institutional Trading of VolitionRx

Several institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp increased its holdings in VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares during the last quarter. Two Sigma Securities LLC acquired a new stake in VolitionRx in the 4th quarter valued at approximately $29,000. Millennium Management LLC acquired a new stake in VolitionRx in the 4th quarter valued at approximately $36,000. Geode Capital Management LLC increased its holdings in VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after purchasing an additional 95,900 shares during the last quarter. Finally, Lagoda Investment Management L.P. increased its holdings in VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after purchasing an additional 1,481,000 shares during the last quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.